摘要
目的探讨罗格列酮对初发2型糖尿病患者血糖、胰岛β细胞功能和炎症因子的影响。方法选择50例2型糖尿病患者予以罗格列酮片4 mg,每日1次,口服,如4周后血糖改善不理想者增至8 mg,每日1次,疗程共12周。观察患者治疗前后血糖、胰岛β细胞功能和血浆炎症因子水平的变化。结果与治疗前比较,患者经罗格列酮治疗12周后,空腹血糖(FBG)、睡前血糖、餐后2 h血糖(2 hPG)和糖化血红蛋白(HbA1C)水平均明显下降(P<0.05或P<0.01);空腹C肽(FCP)和餐后C肽(PCP)水平均明显上升(P<0.05);血浆白介素-6(IL-6)、(hs-CRP)和肿瘤坏死因子-α均明显下降(P<0.01或P<0.05)。结论罗格列酮在降低血糖的同时,还能改善胰岛β细胞功能和降低炎症反应,减轻糖尿病大血管并发症的发生和发展。
Objective To investigate the effect of rosiglitazone on blood glucose, pancreatic β cell function and inflammatory factors in early onset type 2 diabetes patients. Methods All 50 cases of patients with type 2 diabetes were orally given the tablets of rosiglitazone 4 mg once daily, and the dosage will be increased to 8 mg once daily with a course of 12 weeks if the blood glucose dosen＇t reach satisfactory level after four weeks. Observe the blood glucose, the pancreatic β cell func- tion and changes of plasma levels of inflammatory factors of the patients before and after therapy. Results After treated with rosiglitazone for 12 weeks, patients＇ fasting blood glucose （FBG）, bedtime blood glucose, 2 h postprandial blood glucose （2 hPG） and glycated hemoglobin （HbAIC） levels were significantly decreased （P 〈 0.05 or P 〈 0.01） compared with those before treatment, fasting C-peptide （FCP） and postprandial C-peptide （PCP） were significantly increased （P 〈 0.05）; plas- ma white of interleukin -6 （IL-6）, （hs-CRP） and tumor necrosis factor -α were significantly decreased （P 〈 0.01 or P 〈 0.05）. Conclusion Rosiglitazone could not only lower blood glucose, but also improve pancreatic β-cell function and re- duce inflammation, reduce the occurrence and development of diabetic vascular complications.
出处
《中国现代医生》
2012年第32期69-70,共2页
China Modern Doctor
基金
浙江省台州市科技局课题(081KY40)
关键词
罗格列酮
2型糖尿病
血糖
胰岛Β细胞
炎症因子
Rosiglitazone
Type 2 diabetes
Glucose
Pancreatic β cells
Inflammatory factors
